Nevertheless, inconsistency in Ki-67 assessment in moderately differentiated breast cancer is widely observed and the use of Ki-67 biomarker is controversially discussed as a parameter for treatment decisions in such breast cancer patients. This evidence concerns the gene MKI67 and breast carcinoma.